GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.

Pabuccu R, Onalan G, Kaya C

Fertility and sterility10 Apr 2007Cited by 50 (Europe PMC)

PMID17428479DOI10.1016/j.fertnstert.2006.12.046PepBankPUB-17428479

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with mild-to-moderate endometriosis, cetrorelix and GnRH agonist protocols produced similar ovarian hyperstimulation outcomes.
In plain wordsIn patients with mild-to-moderate endometriosis, ovarian stimulation outcomes were similar with cetrorelix and the agonist protocol.
Peptide
Cetrorelix
Outcome
Direction not reportedControlled ovarian hyperstimulation outcomes in mild-to-moderate endometriosis
Study
n = 98
Comparator
Triptrolein
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Outcomes of COH with both GnRH antagonist and GnRH-a were similar in patients with mild-to-moderate endometriosis.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 246 ICSI cycles in 246 patients were divided into three groups: women with mild-to-moderate endometriosis (n = 98); women who had ovarian surgery for endometrioma (n = 81); women with endometrioma and no history of previous surgery (n = 67).
Summary · context
Patients in each group were randomized to COH with either triptrolein or cetrorelix.
Report a problemFND-1742847901
02HumanRandomized controlled trialEfficacy outcome
After endometrioma surgery, implantation rates were 15.9% with cetrorelix versus 22.6% with the agonist protocol.
In plain wordsAfter endometrioma surgery, implantation rates were 15.9% with cetrorelix versus 22.6% with the agonist protocol.
Peptide
Cetrorelix
Outcome
DecreaseImplantation after endometrioma surgery
Study
n = 81
Comparator
Triptrolein
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Implantation rate
15.9%
cetrorelix
Implantation rate
22.6%
agonist
Source sentences
Summary
Implantation rates were 15.9% vs. 22.6% and clinical pregnancy rates were 27.5% vs. 39% with GnRH antagonist and GnRH-a protocols, respectively, in patients who had ovarian surgery for endometrioma.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 246 ICSI cycles in 246 patients were divided into three groups: women with mild-to-moderate endometriosis (n = 98); women who had ovarian surgery for endometrioma (n = 81); women with endometrioma and no history of previous surgery (n = 67).
Summary · context
Patients in each group were randomized to COH with either triptrolein or cetrorelix.
Report a problemFND-1742847902
03HumanRandomized controlled trialEfficacy outcome
After endometrioma surgery, clinical pregnancy rates were 27.5% with cetrorelix versus 39% with the agonist protocol.
In plain wordsAfter endometrioma surgery, pregnancy rates were 27.5% with cetrorelix versus 39% with the agonist protocol.
Peptide
Cetrorelix
Outcome
DecreaseClinical pregnancy after endometrioma surgery
Study
n = 81
Comparator
Triptrolein
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Clinical pregnancy rate
27.5%
cetrorelix
Clinical pregnancy rate
39%
agonist
Source sentences
Summary
Implantation rates were 15.9% vs. 22.6% and clinical pregnancy rates were 27.5% vs. 39% with GnRH antagonist and GnRH-a protocols, respectively, in patients who had ovarian surgery for endometrioma.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 246 ICSI cycles in 246 patients were divided into three groups: women with mild-to-moderate endometriosis (n = 98); women who had ovarian surgery for endometrioma (n = 81); women with endometrioma and no history of previous surgery (n = 67).
Summary · context
Patients in each group were randomized to COH with either triptrolein or cetrorelix.
Report a problemFND-1742847903
04HumanRandomized controlled trialEfficacy outcome
In patients with unoperated endometrioma, implantation rates were 12.5% with cetrorelix versus 14.8% with the agonist protocol.
In plain wordsIn patients with unoperated endometrioma, implantation rates were 12.5% with cetrorelix versus 14.8% with the agonist protocol.
Peptide
Cetrorelix
Outcome
DecreaseImplantation without endometrioma surgery
Study
n = 67
Comparator
Triptrolein
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Implantation rate
12.5%
cetrorelix
Implantation rate
14.8%
agonist
Source sentences
Summary
Implantation rates were 12.5% vs. 14.8% and clinical pregnancy rates were 20.5% vs. 24.2% with GnRH antagonist and GnRH-a protocols, respectively, in patients with endometrioma and no history of ovarian surgery.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 246 ICSI cycles in 246 patients were divided into three groups: women with mild-to-moderate endometriosis (n = 98); women who had ovarian surgery for endometrioma (n = 81); women with endometrioma and no history of previous surgery (n = 67).
Summary · context
Patients in each group were randomized to COH with either triptrolein or cetrorelix.
Report a problemFND-1742847904
05HumanRandomized controlled trialEfficacy outcome
In patients with unoperated endometrioma, clinical pregnancy rates were 20.5% with cetrorelix versus 24.2% with the agonist protocol.
In plain wordsIn patients with unoperated endometrioma, pregnancy rates were 20.5% with cetrorelix versus 24.2% with the agonist protocol.
Peptide
Cetrorelix
Outcome
DecreaseClinical pregnancy without endometrioma surgery
Study
n = 67
Comparator
Triptrolein
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Clinical pregnancy rate
20.5%
cetrorelix
Clinical pregnancy rate
24.2%
agonist
Source sentences
Summary
Implantation rates were 12.5% vs. 14.8% and clinical pregnancy rates were 20.5% vs. 24.2% with GnRH antagonist and GnRH-a protocols, respectively, in patients with endometrioma and no history of ovarian surgery.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 246 ICSI cycles in 246 patients were divided into three groups: women with mild-to-moderate endometriosis (n = 98); women who had ovarian surgery for endometrioma (n = 81); women with endometrioma and no history of previous surgery (n = 67).
Summary · context
Patients in each group were randomized to COH with either triptrolein or cetrorelix.
Report a problemFND-1742847905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.